Perspective Therapeutics, Inc.
AMEX:CATXMedical - Devices
+$0.02 today
- Market cap
- $94.67M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$107.27
Volume 1.84M
Average 1.44M
Returns on capital
Perspective Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.8%
avg -49.3%
ROIC
-47.0%
avg -41.7%
ROA
-38.6%
avg -38.3%
Analysis
ROA is currently the strongest return metric at -38.6% versus its period average of -38.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Johan Spoor | Chief Executive Officer & Director | USD 1.1M | 54 | — | — |
Markus Puhlmann | Chief Medical Officer | USD 737.4K | 60 | 178.54K | 0.23% |
Jonathan R. Hunt | Chief Accounting Officer | USD 611.17K | 59 | — | — |
Joel David Sendek | CFO & Principal Financial Officer | USD 574.29K | 59 | — | — |
Michael K. Schultz | Co-Founder & Senior Scientific Advisor | — | — | — | — |
Paul Lyne | Chief Science Officer | — | — | — | — |
Andrew Bright | Executive Vice President of Brachytherapy | — | — | — | — |
Chris Nenno | General Counsel & Corporate Secretary | — | — | — | — |
Shane Cobb | Executive Vice President of Operations | — | — | — | — |
Annie J. Cheng | Vice President of Investor Relations | — | 50 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 12, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$72,487.60
Sells
7
$1.62M
Net Transaction Value
−$1.55M
Net selling
Most Active
Lantheus Alpha Therapy, LLC
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 12, 26Nov 12, 2026 | Puhlmann Markus Direct | Buy | $29.6K$29,564.50 |
| Nov 11, 26Nov 11, 2026 | Puhlmann Markus Direct | Buy | $5K$4,980.00 |
| Nov 11, 26Nov 11, 2026 | Spoor Johan M. Direct | Buy | $37.9K$37,943.10 |
| Sep 4, 26Sep 4, 2026 | Lantheus Alpha Therapy, LLC Direct | Sell | $526.1K$526,051.33 |
| Sep 3, 26Sep 3, 2026 | Lantheus Alpha Therapy, LLC Direct | Sell | $250.9K$250,895.84 |
| Sep 2, 26Sep 2, 2026 | Lantheus Alpha Therapy, LLC Direct | Sell | $131.2K$131,219.20 |
| Sep 1, 26Sep 1, 2026 | Lantheus Alpha Therapy, LLC Direct | Sell | $111.6K$111,574.24 |
| Sep 1, 26Sep 1, 2026 | Lantheus Holdings, Inc. Direct | Sell | $111.6K$111,574.24 |
| Aug 31, 26Aug 31, 2026 | Lantheus Holdings, Inc. Direct | Sell | $245.6K$245,609.74 |
| Aug 31, 26Aug 31, 2026 | Lantheus Alpha Therapy, LLC Direct | Sell | $245.6K$245,609.74 |
Summary
Insiders reported 3 buys worth $72,487.60 and 7 sells worth $1.62M over the last 12 months. That adds up to net selling of $1.55M. Lantheus Alpha Therapy, LLC was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -50.1% | +140.8% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -50.1% over three years. Forward estimates point to Revenue at +140.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Perspective Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CATX's management, answered from reported figures.
Who manages CATX?
Perspective Therapeutics, Inc. (CATX) lists 10 active executives. The top listed executive is Markus Puhlmann, Chief Medical Officer.
Are CATX insiders buying or selling?
Recent insider activity shows net buying of $79.65M.
Continue the stock analysis
Jump to another research area for this company.